Table 1 Characteristics of the 162 estrogen receptor-positive and lymph node positive breast cancer patients treated with anthracyclines.
Training Set† | Validation Set | |||
|---|---|---|---|---|
All | Distant Metastasis | All | Distant Metastasis | |
Total Number of Patients | 84 (100%) | 39 | 78 (100%) | 25 |
Follow-up | ||||
Median follow-up [Months] | 80 | 53.5 | ||
Range [Months] | 6-144 | 5-166 | ||
Age at Diagnosis | ||||
≤ 50 Years | 38 (45%) | 20 | 41 (53%) | 16 |
> 50 Years | 46 (55%) | 19 | 37 (47%) | 19 |
Median Age (Years) | 49 | 49 | ||
Range (Years) | 29-71 | 33 - 81 | ||
T stage | ||||
≤ 2 cm (T1) | 19 (23%) | 4 | 24 (31%) | 5 |
> 2 cm (T2+T3) | 63 (75%) | 35 | 53 (68%) | 19 |
Unknown | 2 (2%) | 0 | 1 (1%) | 1 |
Tumor Grade | ||||
G1 | 2 (2%) | 0 | 3 (4%) | 1 |
G2 | 24 (29%) | 11 | 30 (38%) | 7 |
G3 | 47 (56%) | 21 | 28 (36%) | 11 |
Unknown | 11 (13%) | 7 | 17 (22%) | 6 |
Estrogen Receptor Status | ||||
Negative | 0 | 0 | 0 | 0 |
Positive | 84 (100%) | 39 | 78 (100%) | 25 |
Progesterone Receptor Status | ||||
Negative | 12 (14%) | 4 | 18 (23%) | 9 |
Positive | 72 (86%) | 35 | 60 (77%) | 16 |
Endocrine Treatment | ||||
Yes | 22 (26%) | 8 | 37 (47%) | 9 |
No | 61 (73%) | 30 | 40 (51%) | 15 |
Unknown | 1 (1%) | 1 | 1 (1%) | 1 |